Treatment patterns among psoriasis patients newly initiated on etanercept or apremilast in a dermatology specialty electronic medical record (EMR) database

Background: Plaque psoriasis (PSO) is a common inflammatory skin disorder that can require chronic treatment. Etanercept (ETN) is a self-injectable biologic indicated to treat moderate-to-severe PSO. Apremilast (APR) is a nonbiologic oral therapy recently approved to treat moderate-to-severe PSO. We sought to examine the real-world treatment patterns of these agents.